Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

被引:42
作者
Du, Yong [1 ]
Carrio, Ignasi [2 ]
De Vincentis, Giuseppe [3 ]
Fanti, Stefano [4 ]
Ilhan, Harun [5 ]
Mommsen, Caroline [6 ]
Nitzsche, Egbert [7 ]
Sundram, Francis [8 ]
Vogel, Wouter [9 ]
Oyen, Wim [1 ,10 ]
Lewington, Val [11 ]
机构
[1] Royal Marsden NHS Fdn Trust, Dept Nucl Med & PET CT, Fulham Rd, London SW3 6JJ, England
[2] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[3] Policlin Umberto I Univ Hosp Rome, Rome, Italy
[4] Univ Hosp Bologna, Bologna, Italy
[5] Ludwig Maximilians Univ Hosp, Munich, Germany
[6] Nuklearmed Berlin, Berlin, Germany
[7] Canton Hosp Aarau, Aarau, Switzerland
[8] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England
[9] Netherlands Canc Inst, Amsterdam, Netherlands
[10] Inst Canc Res, London, England
[11] Guys & St Thomas NHS Fdn Trust, London, England
关键词
Bone metastases; Castration-resistant prostate cancer; Nuclearmedicine; Radiumdichloride; Ra-223; Targeted alpha therapy; EARLY ACCESS; THERAPIES; SURVIVAL;
D O I
10.1007/s00259-017-3756-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Radium Ra 223 dichloride (radium-223, Xofigo (R)) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach. We provide straightforward and practical recommendations for European nuclear medicine centres to optimize radium-223 service provision. Methods An independent research consultancy agency observed radium-223 procedures and conducted interviews with all key staff members involved in radium-223 treatment delivery in 11 nuclear medicine centres across six countries (Germany, Italy, the Netherlands, Spain, Switzerland and the UK) experienced in administering radium-223. The findings were collated and discussed at a meeting of experts from these centres, during which key consensus recommendations were defined. Results The recommendations cover centre organization and preparation; patient referral; radium-223 ordering, preparation and disposal; radium-223 treatment delivery/administration; and patient experience. Guidance includes structured coordination and communication within centres and multidisciplinary teams, focusing on sharing best practice to provide high-quality, patient-centred care throughout the treatment pathway. Conclusions These expert recommendations are intended to complement existing management guidelines. Sharing best practice and experience will help nuclear medicine centres to optimize radium-223 service provision and improve patient care.
引用
收藏
页码:1671 / 1678
页数:8
相关论文
共 15 条
[1]  
[Anonymous], 2015, J CLIN ONCOL
[2]   Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline [J].
Basch, Ethan ;
Loblaw, D. Andrew ;
Oliver, Thomas K. ;
Carducci, Michael ;
Chen, Ronald C. ;
Frame, James N. ;
Garrels, Kristina ;
Hotte, Sebastien ;
Kattan, Michael W. ;
Raghavan, Derek ;
Saad, Fred ;
Taplin, Mary-Ellen ;
Walker-Dilks, Cindy ;
Williams, James ;
Winquist, Eric ;
Bennett, Charles L. ;
Wootton, Ted ;
Rumble, R. Bryan ;
Dusetzina, Stacie B. ;
Virgo, Katherine S. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (30) :3436-U133
[3]  
Bayer AG, RADIUM 223 DICHLORID
[4]  
Bayer HealthCare Pharmaceuticals Inc, RAD RA 223 DICHL FDA
[5]   Targeting bone metastases in prostate cancer: improving clinical outcome [J].
Body, Jean-Jacques ;
Casimiro, Sandra ;
Costa, Luis .
NATURE REVIEWS UROLOGY, 2015, 12 (06) :340-356
[6]   High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra:: Adjuvant or alternative to conventional modalities? [J].
Bruland, Oyvind S. ;
Nilsson, Sten ;
Fisher, Darrell R. ;
Larsen, Roy H. .
CLINICAL CANCER RESEARCH, 2006, 12 (20) :6250S-6257S
[7]  
Henriksen G, 2002, CANCER RES, V62, P3120
[8]  
Mottet N, 2016, GUIDELINES PROSTATE
[9]  
*NAT COMPR CANC NE, 2017, NCCN CLIN PRACT GUID
[10]   Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer [J].
Nilsson, Sten .
CURRENT ONCOLOGY REPORTS, 2016, 18 (02) :1-12